Amgen Inc.

NasdaqGS:AMGN

Market Cap

USD 146.49 B

Share Price

USD 272.44

Avg Daily Volume

3,086,068

Change (1 day)

-5.84%

Change (1 year)

-11.59%

Change (YTD)

4.53%

Amgen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2025: USD 63.42

Amgen Inc. Revenue Per Share is USD 63.42 for the Trailing 12 Months (TTM) ending March 31, 2025, a 14.94% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Amgen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 55.17, a 12.66% change year over year.
  • Amgen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 48.98, a 4.69% change year over year.
  • Amgen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 46.78, a 8.34% change year over year.
  • Amgen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 43.18, a 7.61% change year over year.
Key data
Date Revenue Per Share Free Cash Flow Per Share Dividend Per Share Debt to Equity Ratio
Market news
Loading...
NasdaqGS: AMGN

Amgen Inc.

CEO Mr. Robert A. Bradway
IPO Date June 17, 1983
Location United States
Headquarters One Amgen Center Drive
Employees 28,000
Sector 🏥 Health Care
Industries
Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Similar companies

LLY

Eli Lilly and Company

USD 770.64

1.04%

ABBV

AbbVie Inc.

USD 183.76

-0.83%

RO.SW

Roche Holding AG

USD 339.66

0.85%

AZN.L

AstraZeneca PLC

USD 140.89

0.81%

MRK

Merck & Co., Inc.

USD 80.16

1.39%

PFE

Pfizer Inc.

USD 24.03

0.25%

GILD

Gilead Sciences, Inc.

USD 106.19

-2.13%

SAN.PA

Sanofi

USD 96.16

0.29%

BMY

Bristol-Myers Squibb Company

USD 46.92

0.13%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 51.71

0.69%

GSK.L

GSK plc

USD 18.97

0.58%

COR

Cencora, Inc.

USD 293.13

-0.18%

REGN

Regeneron Pharmaceuticals, Inc.

USD 511.92

0.43%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.24

0.15%

HLN.L

Haleon plc

USD 5.19

0.41%

4502.T

Takeda Pharmaceutical Company Limited

USD 29.87

1.96%

4568.T

Daiichi Sankyo Company, Limited

USD 23.15

2.56%

UCB.BR

UCB SA

USD 190.31

4.88%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.73

2.31%

TEVA.TA

Teva Pharmaceutical Industries Limited

USD 17.10

-0.70%

INSM

Insmed Incorporated

USD 105.42

2.67%

WST

West Pharmaceutical Services, Inc.

USD 216.70

0.41%

SMMT

Summit Therapeutics Inc.

USD 20.39

-0.83%

CIPLA.NS

Cipla Limited

USD 17.50

0.80%

UTHR

United Therapeutics Corporation

USD 286.39

-1.50%

DRREDDY.NS

Dr. Reddy's Laboratories Limited

USD 15.44

1.18%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 36.76

0.26%

1177.HK

Sino Biopharmaceutical Limited

USD 0.67

1.78%

ZYDUSLIFE.NS

Zydus Lifesciences Limited

USD 11.12

0.85%

1093.HK

CSPC Pharmaceutical Group Limited

USD 1.01

3.28%

MANKIND.NS

Mankind Pharma Limited

USD 26.77

0.47%

ASND

Ascendis Pharma A/S

USD 175.78

-0.63%

BMRN

BioMarin Pharmaceutical Inc.

USD 54.08

-1.67%

VTRS

Viatris Inc.

USD 8.85

-0.22%

ORNBV.HE

Orion Oyj

USD 73.97

1.03%

LUPIN.NS

Lupin Limited

USD 22.60

1.25%

000963.SZ

Huadong Medicine Co., Ltd

USD 5.55

-4.21%

IPN.PA

Ipsen S.A.

USD 116.69

0.38%

SOBI.ST

Swedish Orphan Biovitrum AB (publ)

USD 28.73

1.93%

4151.T

Kyowa Kirin Co., Ltd.

USD 17.15

1.10%

2196.HK

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

USD 2.06

1.80%

2607.HK

Shanghai Pharmaceuticals Holding Co., Ltd

USD 1.50

1.42%

ABBOTINDIA.NS

Abbott India Limited

USD 362.33

0.75%

4523.T

Eisai Co., Ltd.

USD 27.34

1.19%

002422.SZ

Sichuan Kelun Pharmaceutical Co., Ltd.

USD 4.82

1.55%

1099.HK

Sinopharm Group Co. Ltd.

USD 2.38

1.23%

002294.SZ

Shenzhen Salubris Pharmaceuticals Co., Ltd.

USD 6.71

2.40%

600085.SS

Beijing Tongrentang Co., Ltd

USD 5.01

-0.21%

002653.SZ

Haisco Pharmaceutical Group Co., Ltd.

USD 5.95

4.00%

GLAXO.NS

GlaxoSmithKline Pharmaceuticals Limited

USD 37.17

1.19%

StockViz Staff

June 24, 2025

Any question? Send us an email